NCT04789837

The Phosphodiesterase 3 Inhibitor Cilostazol as an Adjunct to Conventional Therapy in Patients With Osteoarthritis

The Phosphodiesterase 3 Inhibitor Cilostazol as an Adjunct to Conventional Therapy in Patients With Osteoarthritis: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial

• Status: Withdrawn
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Sadat City University · Academic / Other
• Sex: All
• Age: 30 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Cilostazol is able to suppress the degradation of type II collagen in human chondrocytes induced by IL-1b. Cilostazol add-on for celecoxib therapy has synergistic anti-arthritic potential by inhibiting proinflammatory cytokine production in synovial fibroblasts through the IL-10/SOCS3 pathways, consequently leading to the inhibition of synovial cell proliferation and overcoming the perpetuation of synovial inflammation.

Conditions

• Osteoarthritis

Interventions

Type	Name	Description
DRUG	Cilostazol 50 MG	Cilostazol 50 mg twice daily plus Celecoxib 200mg capsule
DRUG	Placebo	Placebo tablet twice daily plus Celecoxib 200mg capsule

Timeline

• Start date: 2021-03-01
• Primary completion: 2024-12-30
• Completion: 2024-12-31
• First posted: 2021-03-10
• Last updated: 2025-07-14

Locations

1 site across 1 country: Egypt